Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 3/17/20 → 3/20/23 |
Funding
- Regeneron Pharmaceuticals, Inc. ((OE) Prot #6R88-COV-2040)
Prot #6R88-COV-2040: An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients with COVID-19
- Wunderink, Richard G (PD/PI)
Project: Research project